A switch to MET signaling can drive acquired resistance to EGFR inhibitors, such as erlotinib [56] and gefitinib [57], in NSCLC, and EGFR signaling can drive MET inhibitor resistance [25–26], illustrating the reciprocal nature of signaling between these RTKs. This evidence concerns the gene MET and non-small cell lung carcinoma.